Vontobel Holding Ltd. Sells 14,903 Shares of Edwards Lifesciences Corporation (NYSE:EW)

Vontobel Holding Ltd. lowered its position in shares of Edwards Lifesciences Corporation (NYSE:EW - Free Report) by 3.7% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 384,972 shares of the medical research company's stock after selling 14,903 shares during the period. Vontobel Holding Ltd. owned about 0.07% of Edwards Lifesciences worth $27,903,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Crowley Wealth Management Inc. bought a new position in shares of Edwards Lifesciences during the 4th quarter valued at $26,000. Vega Investment Solutions bought a new position in shares of Edwards Lifesciences during the fourth quarter valued at about $27,000. Millstone Evans Group LLC bought a new position in shares of Edwards Lifesciences during the fourth quarter valued at about $29,000. Global X Japan Co. Ltd. increased its holdings in shares of Edwards Lifesciences by 116.1% in the first quarter. Global X Japan Co. Ltd. now owns 402 shares of the medical research company's stock worth $29,000 after buying an additional 216 shares during the period. Finally, Tradewinds Capital Management LLC lifted its stake in shares of Edwards Lifesciences by 102.5% in the 1st quarter. Tradewinds Capital Management LLC now owns 405 shares of the medical research company's stock valued at $29,000 after acquiring an additional 205 shares during the last quarter. 79.46% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity

In related news, VP Daveen Chopra sold 1,500 shares of the company's stock in a transaction that occurred on Thursday, May 22nd. The stock was sold at an average price of $75.08, for a total value of $112,620.00. Following the sale, the vice president owned 33,496 shares in the company, valued at $2,514,879.68. This represents a 4.29% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, insider Larry L. Wood sold 8,950 shares of the business's stock in a transaction on Monday, June 16th. The stock was sold at an average price of $75.23, for a total value of $673,308.50. Following the completion of the sale, the insider directly owned 206,900 shares in the company, valued at $15,565,087. This trade represents a 4.15% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 40,648 shares of company stock valued at $2,998,866. 1.29% of the stock is currently owned by insiders.

Analysts Set New Price Targets

Several equities analysts recently issued reports on EW shares. Dbs Bank upgraded Edwards Lifesciences to a "hold" rating in a research report on Monday, June 2nd. Citigroup restated a "buy" rating and issued a $95.00 target price (up previously from $84.00) on shares of Edwards Lifesciences in a report on Thursday, May 22nd. Truist Financial lowered their price target on shares of Edwards Lifesciences from $78.00 to $75.00 and set a "hold" rating for the company in a report on Friday, April 11th. Piper Sandler increased their price target on shares of Edwards Lifesciences from $80.00 to $83.00 and gave the company an "overweight" rating in a research report on Tuesday, May 13th. Finally, Wall Street Zen cut shares of Edwards Lifesciences from a "buy" rating to a "hold" rating in a research report on Friday, May 16th. One research analyst has rated the stock with a sell rating, fourteen have issued a hold rating and eleven have assigned a buy rating to the company. According to MarketBeat, the stock currently has an average rating of "Hold" and a consensus target price of $80.20.

Edwards Lifesciences Stock Down 0.3%

Edwards Lifesciences stock traded down $0.25 on Friday, hitting $76.77. 1,679,364 shares of the stock traded hands, compared to its average volume of 5,253,911. Edwards Lifesciences Corporation has a 1 year low of $58.93 and a 1 year high of $95.25. The firm has a market cap of $45.03 billion, a P/E ratio of 10.97, a price-to-earnings-growth ratio of 3.86 and a beta of 1.11. The company has a current ratio of 4.45, a quick ratio of 3.66 and a debt-to-equity ratio of 0.06. The business's fifty day simple moving average is $76.12 and its 200 day simple moving average is $73.28.

Edwards Lifesciences (NYSE:EW - Get Free Report) last issued its quarterly earnings results on Wednesday, April 23rd. The medical research company reported $0.64 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.60 by $0.04. Edwards Lifesciences had a net margin of 75.48% and a return on equity of 16.62%. The company had revenue of $1.41 billion during the quarter, compared to analyst estimates of $1.40 billion. During the same period last year, the business earned $0.66 EPS. Edwards Lifesciences's quarterly revenue was up 6.2% compared to the same quarter last year. As a group, sell-side analysts forecast that Edwards Lifesciences Corporation will post 2.45 earnings per share for the current year.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.